HPSE and plasma cell myeloma: OGT2115 is a small molecule inhibitor, but in the myeloma cells, it is not known whether it is blocking heparanase activity within the cytoplasm and inhibiting transport to the nucleus, or it is present in the nucleus, where it could block heparanase activity resulting in loss of nuclear heparanase.